Innoviva Q1 net loss $46.6M on $78.8M investment write-down; IST sales up 52%

Innoviva, Inc.

2025-Q1 EPS reported -$0.74 revenue$88,632,000

Net loss of $46.6M ($0.74/share) vs net income of $36.5M in Q1 2024 due to $78.8M unfavorable fair value changes on equity investments.
Royalty revenue from GSK was $61.3M, largely flat year-over-year.
U.S. net product sales from IST (GIAPREZA, XACDURO, XERAVA) grew 52% to $26.4M; total net product sales $30.3M.
Income from operations rose 61% to $41.4M; cash and equivalents $319.1M at quarter end.
Zoliflodacin NDA on track for H1 2025 filing; ZEVTERA U.S. launch expected mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.